3'-p-Hydroxy paclitaxel
CAS: 132160-32-8
Ref. 3D-FH24081
1mg | Descontinuado | ||
50µg | Descontinuado | ||
100µg | Descontinuado | ||
250µg | Descontinuado | ||
500µg | Descontinuado |
Informação sobre produto
- 3'-Para-hydroxypaclitaxel
- (2alpha,5beta,7beta,10beta,13alpha)-4,10-bis(acetyloxy)-1,7-dihydroxy-13-({(2R,3S)-2-hydroxy-3-(4-hydroxyphenyl)-3-[(phenylcarbonyl)amino]propanoyl}oxy)-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
- 3′-Para-hydroxypaclitaxel
- 3′-p-Hydroxypaclitaxel
- Benzenepropanoic acid, β-(benzoylamino)-α,4-dihydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-
- Benzenepropanoic acid, β-(benzoylamino)-α,4-dihydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-4-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]]-
- P-3'-Hydroxypaclitaxel Standard
3'-p-Hydroxy paclitaxel is a cytotoxic drug that was originally developed to treat cancer. It has been shown to inhibit the growth of tumor cells in human liver, as well as other tissues. 3'-p-Hydroxy paclitaxel binds to cell membranes and forms pores that disrupt cell function. The drug also inhibits the production of colony-stimulating factor in plasma samples, which may be due to its ability to inhibit enzyme activities such as protein synthesis. 3'-p-Hydroxy paclitaxel is metabolized by various enzymes into metabolic products that are excreted through urine or bile. In one pharmacokinetic study, it was found that 3'-p-hydroxypaclitaxel accumulates in fatty tissues. This accumulation may lead to toxic effects on the liver and heart.